Recombinant Mouse TIGIT protein (His tag) is a Mouse Fragment protein, in the 26 to 135 aa range, expressed in HEK 293, with >95% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE.
G T I D T K R N I S A E E G G S V I L Q C H F S S D T A E V T Q V D W K Q Q D Q L L A I Y S V D L G W H V A S V F S D R V V P G P S L G L T F Q S L T M N D T G E Y F C T Y H T Y P G G I Y K G R I F L K V Q E S S V A Q F G G G G S H H H H H H
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Select an associated product type
Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades. In addition, associates with beta-arrestin-2/ARRB2 to recruit SHIP1/INPP5D that suppresses autoubiquitination of TRAF6 and subsequently inhibits NF-kappa-B signaling pathway. Acts also as a receptor for NECTIN4 to inhibit NK cell cytotoxicity.
Vstm3, Tigit, T-cell immunoreceptor with Ig and ITIM domains, V-set and transmembrane domain-containing protein 3
Recombinant Mouse TIGIT protein (His tag) is a Mouse Fragment protein, in the 26 to 135 aa range, expressed in HEK 293, with >95% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE.
pH: 7.4
Constituents: 100% PBS
Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades. In addition, associates with beta-arrestin-2/ARRB2 to recruit SHIP1/INPP5D that suppresses autoubiquitination of TRAF6 and subsequently inhibits NF-kappa-B signaling pathway. Acts also as a receptor for NECTIN4 to inhibit NK cell cytotoxicity.
TIGIT also known as T cell immunoreceptor with Ig and ITIM domains is an immunoglobulin superfamily receptor. It weighs approximately 26 kDa. TIGIT commonly expresses on T cells especially on regulatory T cells (Tregs) and effector memory T cells. It also presents on natural killer (NK) cells. Among its alternate forms some notable ones also include the anti-TIGIT and biotinylated TIGIT antibodies used in experimental research to monitor immune responses.
TIGIT acts as an inhibitory receptor modulating immune responses. It belongs to the CD28 family and binds to poliovirus receptor (PVR) and nectin-2 on antigen-presenting cells. This interaction inhibits T cell activation and proliferation and increases Treg cell activity maintaining immune homeostasis. TIGIT forms a complex with other inhibitory receptors like PD-1 2B4 and CD96 to further regulate immune functions.
The interaction of TIGIT with its ligands significantly affects the immune checkpoint pathway. This involvement regulates T cell and NK cell activity. TIGIT is related to CD226 (DNAM-1) which competes for binding to its ligands influencing cellular signaling pathways. Through these pathways TIGIT signals through the downstream SHP-1 and SHP-2 proteins affecting immune cell signaling and response.
TIGIT has implications in cancer and autoimmune diseases. Its inhibitory function can allow tumor progression by dampening effective anti-tumor immunity. In cancer TIGIT’s activity often pairs with PD-1 both contributing to immune checkpoint blockade resistance necessary for tumor evasion. In autoimmune diseases increased TIGIT expression could result in reduced immune cell attack against self tissues showing its potential to modulate treatment strategies.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com